A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential-Panel, Ascending Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-020 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 29 May 2017
At a glance
- Drugs TAK 020 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Takeda
- 23 May 2017 Status changed from recruiting to completed.
- 25 Oct 2016 Planned number of patients changed from 136 to 128.
- 25 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 May 2017.